Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: GlobeNewswire
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today reported second quarter 2024 financial results and provided operational h
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $23.00 price target on the stock.MarketBeat
- Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target lowered by analysts at HC Wainwright from $22.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $24.00 price target on the stock.MarketBeat
LXEO
Sec Filings
- 9/11/24 - Form 4
- 9/10/24 - Form 144
- 8/13/24 - Form 4
- LXEO's page on the SEC website